Tirzepatide Mechanism of Action: The Dual GIP/GLP-1 Receptor Pharmacology
The short version
Tirzepatide mechanism of action comes down to one sentence: a single engineered peptide activates both the GIP and GLP-1 receptors simultaneously, and the way it does so — imbalanced and biased — produces larger metabolic effects than activating GLP-1 alone. This page unpacks what that means at the receptor level and why those molecular details connect to the clinical-trial outcomes.
GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are both gut hormones — incretin hormones — released after a meal to stimulate insulin secretion in a glucose-dependent fashion (only when blood sugar is elevated, which is why they carry low hypoglycaemia risk). Tirzepatide is a 39-amino-acid synthetic peptide engineered from the GIP backbone, acylated with a C20 fatty-diacid arm that gives it a five-day half-life and once-weekly dosing.
Receptor engagement: imbalanced and biased dual agonism
The tirzepatide mechanism of action was characterised in depth by Willard et al. (2020) in JCI Insight [2]. The key finding: tirzepatide is an imbalanced dual agonist. It engages the GIP receptor (GIPR) to a greater degree than the GLP-1 receptor (GLP-1R) in receptor-occupancy assays. Most prior work assumed a balanced dual agonist would be optimal; tirzepatide's imbalanced favouring of GIPR engagement appears to be a feature, not a bug.
The second layer is biased agonism at the GLP-1R. Receptors couple to multiple downstream signalling pathways; which pathway is activated depends partly on the ligand. Tirzepatide favours cAMP generation (the pathway that triggers insulin secretion) over beta-arrestin recruitment (the pathway that causes the receptor to be internalised — pulled inside the cell and silenced). In primary islet experiments, beta-arrestin1 limited the insulin response to GLP-1 but not to GIP or tirzepatide — meaning tirzepatide's biased GLP-1R signalling avoids the beta-arrestin brake [2].
Douros et al. (2024) reviewed this biased agonism concept in the Journal of Endocrinology, concluding that tirzepatide's preferential Gαs activation over β-arrestin recruitment contributes to its insulinotropic and body-weight-reducing effects and frames biased GLP-1R agonism as a mechanism for clinical differentiation within the drug class [9].
Novikoff et al. (2021) added receptor-trafficking data using BRET assays and live-cell HILO microscopy: tirzepatide preserved maximal cAMP production despite only partial Gαs protein recruitment — and this was paired with diminished receptor internalisation at both GLP-1R and GIPR [4]. Receptors that are not internalised stay on the cell surface and continue signalling; this sustained surface residence may be a component of the prolonged and potent insulinotropic effect.
The structural basis of dual-receptor engagement
Sun et al. (2022, Proc Natl Acad Sci) used cryo-electron microscopy to determine the structural determinants of how tirzepatide simultaneously engages the GIP and GLP-1 receptors [7]. The study clarified the molecular basis of dual incretin receptor agonism — specifically, how a single acylated peptide can bind both the GIPR and GLP-1R at their extracellular domains and transduce signalling through both.
The peptide backbone of tirzepatide (39 amino acids, built on the native GIP sequence) positions key residues for GIP receptor engagement at the N-terminus and GLP-1 receptor engagement further along the sequence — a structural strategy that allows the same molecule to dock productively at two different receptor architectures. The C20 fatty-diacid acylation arm attached to a mid-sequence lysine residue (via a glutamic acid linker and two AEEA spacer units) does not contribute to receptor docking per se but confers albumin binding, extending the half-life from minutes (native peptides) to approximately five days [1].
The GIP arm: adipose and central actions distinct from GLP-1
One of the mechanistic advances clarified since tirzepatide's approval is the specific contribution of the GIPR arm to its effects — particularly in adipose tissue and the central nervous system.
Regmi et al. (2024, Cell Metab) showed that long-acting GIPR agonism cooperates with insulin to augment glucose uptake and lipid clearance in human adipocytes in the fed state, while enhancing lipolysis when insulin is low in the fasted state [8]. This state-dependent adipose nutrient-buffering role — increasing fat-tissue uptake of circulating lipids in the postprandial state, then releasing them as free fatty acids in the fasted state — appears to contribute to reduced circulating triglycerides and the observed favourable fat-loss profile.
Samms et al. (2025, Diabetes) argued in a contemporary mechanistic review that GIPR agonism in the brain attenuates nausea and suppresses appetite synergistically with GLP-1R — meaning the GIP arm may contribute to appetite suppression through a different CNS pathway than the GLP-1 arm [40]. This would explain why the combination outperforms either receptor agonism alone.
Samms et al. (2025, Annu Rev Physiol) synthesised the full incretin gut-brain-adipose axis: multireceptor agonists targeting GLP-1, GIP, and glucagon receptors achieve meaningful weight loss by promoting negative energy balance, with brain GIP-receptor activation and adipose GIP-receptor activity synergising with GLP-1R agonism to suppress appetite and increase substrate utilisation [9].
From receptor pharmacology to clinical outcomes
The mechanism — dual imbalanced biased agonism at GIPR and GLP-1R — connects directly to the clinical-trial outcomes. Larger glycaemic reductions and weight loss than selective GLP-1 receptor agonism were predicted by the dual-receptor discovery work [1] and confirmed in SURPASS-2 and SURMOUNT-5 [3][6].
The glucose-dependent insulin secretion mechanism (both GIPR and GLP-1R stimulate insulin only when blood glucose is elevated) is the structural reason for the low intrinsic hypoglycaemia risk documented in the trial programme — a pharmacological feature shared with the GLP-1 drug class but now operating across two receptor systems [21].
Suppression of glucagon (the pancreatic hormone that raises blood glucose; incretin agonists suppress its secretion at elevated glucose) and delayed gastric emptying (slowing the rate at which the stomach passes its contents into the intestine, blunting postprandial glucose spikes) are both well-established GLP-1R effects that tirzepatide also demonstrates, as confirmed in the phase 1 gastric-emptying study by Urva et al. [28]. These multiple downstream effects — more insulin, less glucagon, slower gastric emptying, less appetite — combine to produce the observed magnitude of HbA1c and weight reductions.